Table 3.
Toxicity spectrum for every intervention based on any grade and grade 3–4 adverse events. The rate of adverse events in each drug.
| Adverse events | Any grade adverse events | 3–4 grade adverse events | ||||||
|---|---|---|---|---|---|---|---|---|
| Diarrhoea | Cab(54) | Reg(33) | Ram(18) | Peb(17) | Cab(10) | Reg(2) | Ram(1) | Peb(1) |
| Hand–foot skin reaction | Reg(52) | Cab(46) | Cab(17) | Reg(13) | ||||
| Fatigue | Cab(45) | Reg(29) | Ram(23) | Peb(19) | Cab(10) | Reg(6) | Ram(2) | Peb(3) |
| Peripheral oedema | Ram(36) | |||||||
| Nausea | Cab(31) | Ram(19) | Reg(11) | Peb(11) | Cab(2) | Peb(1) | ||
| Hypertension | Cab(29) | Reg(23) | Cab(16) | Reg(13) | ||||
| Ascites | Ram(27) | Ram(5) | ||||||
| Vomiting | Cab(26) | |||||||
| Aspartate aminotransferase increased | Peb(23) | Cab(22) | Reg(13) | Peb(13) | Cab(12) | Reg(5) | ||
| Asthenia | Cab(22) | Cab(7) | ||||||
| Constipation | Cab(19) | |||||||
| Dysphonia | Cab(19) | Cab(1) | ||||||
| Headache | Ram(19) | Ram(1) | ||||||
| Blood bilirubin increased | Reg(19) | Peb(19) | Peb(8) | Reg(7) | ||||
| Pruritus | Peb(18) | |||||||
| Abdominal pain | Cab(18) | Ram(17) | Cab(2) | Ram(2) | ||||
| Alanine aminotransferase increased | Peb(18) | Cab(17) | Peb(6) | Cab(5) | ||||
| Decreased appetite | Cab(18) | Reg(24) | Ram(22) | Peb(17) | Cab(6) | Reg(3) | Ram(2) | Peb(1) |
| Pyrexia | Ram(17) | |||||||
| Weight loss | Cab(17) | Cab(1) | ||||||
| Proteinuria | Ram(16) | Ram(2) | ||||||
| Cough | Ram(15) | Peb(9) | ||||||
| Oral mucositis | Reg(11) | Reg(1) | ||||||
The number in parentheses represents the incidence of each adverse event for the drug.
Cab, cabozantinib; Pem, pembrolizumab; Ram, ramucirumab; Reg, regorafenib.